{
  "slug": "tirzepatide",
  "name": "Tirzepatide",
  "aliases": ["GIP/GLP-1 RA", "Mounjaro", "Zepbound"],
  "category_tags": ["metabolic", "weight"],
  "typical_route": ["subQ"],
  "overview": "Tirzepatide is a dual GIP and GLP-1 receptor agonist approved for type 2 diabetes management and chronic weight management. It acts on two incretin hormone pathways to regulate blood sugar and reduce appetite.",
  "what_people_seek": [
    "Weight management support",
    "Blood sugar control (in diabetes care)",
    "Appetite regulation",
    "Metabolic health improvement"
  ],
  "evidence_level": "Strong",
  "risk_level": "Moderate",
  "side_effects_common": [
    "Nausea and vomiting (often dose-dependent)",
    "Diarrhea or constipation",
    "Abdominal discomfort",
    "Decreased appetite",
    "Fatigue",
    "Injection site reactions"
  ],
  "who_should_avoid": [
    "Pregnant or breastfeeding individuals",
    "Those with personal or family history of medullary thyroid carcinoma",
    "People with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)",
    "Individuals with severe gastrointestinal disease",
    "Anyone with hypersensitivity to tirzepatide"
  ],
  "interactions_notes": "May increase hypoglycemia risk when combined with insulin or sulfonylureas. Can delay gastric emptying and affect oral medication absorption. Full medication review with prescriber is essential.",
  "dosing_ranges_literature": "Weight management protocols typically start at 2.5 mg weekly, escalating every 4 weeks to a target maintenance dose (often 5-15 mg weekly) as tolerated. Diabetes dosing may differ. Follow prescriber instructions.",
  "reconstitution": {
    "vial_total_mg": 10,
    "common_diluents_ml": [2],
    "example_doses_mg": [2.5, 5, 7.5, 10, 12.5, 15]
  },
  "storage_notes": "Keep refrigerated before first use. After initial use, some formulations allow room temperature storage for a limited time. Refer to manufacturer guidelines.",
  "references": [
    {
      "id": "ref1",
      "title": "Tirzepatide for Weight Reduction: SURMOUNT Trial Data",
      "source": "PubMed",
      "year": 2022,
      "url": "https://pubmed.ncbi.nlm.nih.gov/example",
      "note": "Clinical trial showing substantial weight loss in adults with obesity."
    },
    {
      "id": "ref2",
      "title": "Dual GIP/GLP-1 Receptor Agonism: Mechanisms and Clinical Impact",
      "source": "Review",
      "year": 2023,
      "url": "https://example.com/dual-agonist-review",
      "note": "Discusses how targeting both pathways may enhance metabolic benefits."
    },
    {
      "id": "ref3",
      "title": "FDA Label: Tirzepatide Injection",
      "source": "Guideline",
      "year": 2023,
      "url": "https://www.accessdata.fda.gov/example-tirz",
      "note": "Official prescribing information with indications, dosing, and safety warnings."
    }
  ],
  "last_reviewed": "2025-11-02"
}
